Therefore, our study aimed to comprehensively assess the prevalence of MUC1, MUC2, MUC5AC, and MUC6 expression in a large cohort of CRC patients, its association with various clinicopathological parameters such as T classification, N classification, lymphovascular invasion, grade, tumor border configuration, mismatch repair (MMR) status, as well as patients’ progression-free and cancer-specific survival. This evidence concerns the gene MUC2 and neoplasm.